Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olopatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD5 | P21918 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olopatadine SCHEMBL1649764 | 1.00 | HRH1 (1.00) | HRH1LMNAPARP1KCNH2HTR2B | |
| Olopatadine SCHEMBL4669 | 1.00 | HRH1 (1.00) | HRH1LMNAPARP1KCNH2HTR2B | |
| Olopatadine SCHEMBL29517420 | 1.00 | HRH1 (1.00) | HRH1LMNAPARP1KCNH2HTR2B | |
| Olopatadine SCHEMBL29359369 | 1.00 | HRH1 (1.00) | HRH1LMNAPARP1KCNH2HTR2B | |
| Olopatadine SCHEMBL23213 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2ALDH1A1 | |
| Olopatadine SCHEMBL5324205 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2ALDH1A1 | |
| Olopatadine SCHEMBL29402772 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2ALDH1A1 | |
| Olopatadine SCHEMBL122589 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2ALDH1A1 | |
| Olopatadine SCHEMBL694414 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2HTR2B | |
| Olopatadine SCHEMBL29381853 | 0.99 | HRH1 (0.98) | HRH1LMNAPARP1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11419 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| CN-122005453-A | Orostatin and budesonide composition nasal spray and preparation method thereof | 江苏德迈药业有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-2922553-B1 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | GLENMARK SPECIALTY SA (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2026-04-23 | — | — | US | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| US-6174524-B1 | Gelling ophthalmic compositions containing xanthan gum | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| US-6174914-B1 | TREATING OR PREVENTING OCULAR NEOVASCULARIZATION AND NONALLERGIC OPTHALMIC INFLAMMATION BY ADMINISTERING 11-(3-DIMETHYLAMINOPROPYLIDENE)-6,11-DIHYDRODIBENZ(B,E)OXEPIN-2-ACETIC ACID OR ITS SALT | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| WO-2000078396-A2 | TOPICAL OPHTHALMIC MAST CELL STABILIZERS FOR TREATING ALLERGIC EYE DISEASES | ALCON LABORATORIES, INC. (US) | 2000-12-28 | — | — | WO | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| EP-1037627-A1 | USE OF 11-(3-DIMETHYLAMINOPROPYLIDENE)-6,11-DIHYDRODIBENZ[B,E]OXEPIN-2-ACETIC ACID AND OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF NON-ALLERGIC OPHTHALMIC INFLAMMATORY DISORDERS AND FOR THE PREVENTION OF OCULAR NEOVASCULARIZATION | Alcon Laboratories, Inc. (US) | 2000-09-27 | — | — | EP | claimed |
| WO-2000003705-A1 | USE OF 11-(3-DIMETHYLAMINOPROPYLIDENE)-6,11-DIHYDRODIBENZ[B,E]OXEPIN-2-ACETIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING NON-ALLERGIC OPHTHALMIC INFLAMMATORY DISORDERS AND FOR THE PREVENTION OF OCULAR NEOVASCULARIZATION | ALCON LABORATORIES, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999051273-A1 | GELLING OPHTHALMIC COMPOSITIONS CONTAINING XANTHAN GUM | ALCON LABORATORIES, INC. (US) | 1999-10-14 | — | — | WO | claimed |
| EP-0799044-A2 | TOPICAL OPHTHALMIC FORMULATIONS CONTAINING DOXEPIN DERIVATIVES FOR TREATING ALLERGIC EYE DISEASES | ALCON LABORATORIES, INC. (US) | 1997-10-08 | — | — | EP | claimed |
| US-5641805-A | ADMINISTERING TO THE EYE 11-(3-DIMETHYLAMINOPROPYLIDENE)-6,11-DIHYDRODIBENZ(B,E) OXEPIN-2-ACETIC ACID OR SALTS TO TREAT EYE DISEASES SUCH AS CONJUNCTIVITIS | ALCON LABORATORIES, INC. (US) | 1997-06-24 | — | — | US | claimed |
| WO-1996039147-A2 | TOPICAL OPHTHALMIC FORMULATIONS CONTAINING DOXEPIN DERIVATIVES FOR TREATING ALLERGIC EYE DISEASES | ALCON LABORATORIES, INC. (US) | 1996-12-12 | — | — | WO | claimed |